CurrentBlue Cross Blue Shield - MassachusettsPolicy 609

Suprachoroidal Delivery of Pharmacologic Agents

This policy governs coverage for suprachoroidal injection/delivery of pharmacologic agents for posterior segment ocular diseases for Blue Cross Blue Shield - Massachusetts members (commercial and Medicare products). It states the payer's coverage stance and prior authorization requirements relevant to providers.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicySuprachoroidal Delivery of Pharmacologic Agents

Policy CodePolicy 609

Change TypeNo material change

Effective Date

Next Review Date

Key ActionObtain precertification/preauthorization for inpatient services described in this policy.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1procedure code specifically listed as investigational

Investigationalcoverage stance

Precertificationinpatient prior auth

4related policies

Coverage Criteria and Policy Stance

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Investigational / Not Covered Unless Evidence Changes

Coverage stance

Policy determination: Suprachoroidal delivery of pharmacologic agents is considered investigational because evidence is insufficient to determine net health benefit.

All devices for suprachoroidal delivery are considered investigational regardless of commercial name, manufacturer, or FDA approval status.

All devices and approaches for delivering pharmacologic agents into the suprachoroidal space are considered investigational. The suprachoroidal route (injection into the potential space between the choroid and sclera) is an investigational method under study to target posterior segment structures such as the retina, choroid, and macula. While investigational techniques aim to improve local bioavailability and reduce systemic exposure, current evidence is insufficient to establish a net health benefit for any suprachoroidal device or delivery approach.

Suprachoroidal delivery of a pharmacologic agent is investigational and therefore not considered medically necessary based on insufficient evidence of improved net health outcomes. The policy treats all devices for suprachoroidal delivery as investigational regardless of commercial name, manufacturer, or FDA approval status, and claims for such procedures may be denied as not medically necessary.

Provider Requirements and Actions

Prior Authorization

Prior Authorization Required

Precertification/preauthorization is required for inpatient services described in this policy for all products.

Applicable to all products when the procedure is performed inpatient

Step Therapy

No step therapy requirements are specified for procedures described in this policy.

Documentation Required

Coding and Documentation Guidance

Providers must report services using current industry-standard procedure, revenue, and diagnosis codes and include appropriate modifiers. Use the most up-to-date CPT, HCPCS, ICD-10, revenue, and modifier codes when submitting claims. Inclusion of a code in this policy does not guarantee coverage; verify member benefits at the time of service.

Report services with up-to-date procedure, revenue, and diagnosis codes and modifiers
Inclusion of a code does not imply coverage or reimbursement — check member contract benefits

Denial Risk

Investigational Procedure — Denial Risk

Suprachoroidal delivery of a pharmacologic agent is considered investigational; claims for this procedure may be denied as not medically necessary.

Suprachoroidal delivery of pharmacologic agents — investigational for Commercial members and Medicare products
Claims may be denied as not medically necessary

Definitions

Suprachoroidal delivery / suprachoroidal injection — definition and approaches

DefinitionInjection or delivery of a pharmacologic agent into the suprachoroidal space (the potential space between the choroid and sclera) to target posterior segment ocular structures such as the retina, choroid, and macula.

Typical delivery approachesMicrocannula-based systems (e.g., microcannula with drug channel and fiber‑optic illumination for guidance).

Examples of agents studiedRanibizumab and pegaptanib for age‑related macular degeneration; triamcinolone acetonide for diabetic macular edema/neuropathy.

Potential advantageMay increase local tissue drug levels in the posterior segment while minimizing systemic exposure.

Potential riskRisk of localized tissue damage related to microcannula use.

Device examples and regulatory noteDevice example: iTrack (iScience Interventional). All devices for suprachoroidal delivery are considered investigational regardless of commercial name, manufacturer, or FDA approval status.

Background

Suprachoroidal delivery is an investigational route being studied to deliver drugs to posterior segment ocular diseases (for example, age-related macular degeneration and diabetic retinopathy) where topical and systemic routes often fail to achieve therapeutic levels at the retina and choroid. Examples of agents studied via this route include ranibizumab, pegaptanib, and triamcinolone acetonide, and device systems such as microcannula platforms (for example, the iTrack). Potential advantages include higher local tissue drug levels with reduced systemic exposure; potential risks include localized tissue damage from microcannula use. Current evidence remains insufficient to determine whether suprachoroidal delivery improves net health outcomes, and the procedure is therefore considered investigational.